E J Busuttil

Pharmaceuticals

Empowering better health through trusted partnerships

Meet Our Division Managers

Dedicated professionals leading our Pharmaceuticals division with expertise and passion

Director of Pharmaceuticals & Clinical Affairs

Claire Busuttil

A pharmacist by profession, she leads the Group’s pharmaceutical strategy, strengthening its scientific expertise and commitment to patient-focused solutions.

Director of Pharmaceuticals & Clinical Affairs

Claire Busuttil

A pharmacist by profession, she leads the Group’s pharmaceutical strategy, strengthening its scientific expertise and commitment to patient-focused solutions.

Operations Director

Robert Busuttil

Driving structure, efficiency, and innovation across all divisions, he leads the Group’s operational development and continuous improvement.

Operations Director

Robert Busuttil

Driving structure, efficiency, and innovation across all divisions, he leads the Group’s operational development and continuous improvement.

Director of Pharmaceuticals & Clinical Affairs

Claire Busuttil

A pharmacist by profession, she leads the Group’s pharmaceutical strategy, strengthening its scientific expertise and commitment to patient-focused solutions.

Director of Pharmaceuticals & Clinical Affairs

Claire Busuttil

A pharmacist by profession, she leads the Group’s pharmaceutical strategy, strengthening its scientific expertise and commitment to patient-focused solutions.

Comprehensive Medical Device Solutions

We also supply medical devices_ from gastrointestinal treatments to advanced dermal matrices_ ensuring comprehensive support across clinical, hospital, and community settings.

Empowering Better Health Through Trusted Partnerships

At E.J. Busuttil Ltd., our pharmaceutical Division serves as a key link between global innovation and Malta’s healthcare needs. Through long-standing partnerships with leading research- driven multinational companies, as well as reputable generic and biological manufacturers, we ensure broad access to safe, effective, and evidence-based medicines across both the public and private markets.